Prof. Wai-Kay Seto graduated from the University of Hong Kong in 2003 and received his Fellowship in Gastroenterology and Hepatology in 2010 from the Hong Kong College of Physicians. He received his Doctor of Medicine from the University of Hong Kong in 2012. He is currently the Simon KY Lee Professor in Gastroenterology in the Department of Medicine, and Principal Investigator of the State Key Laboratory of Liver Disease, the University of Hong Kong, Hong Kong. He is also the Chair of Division and Chief Physician in Gastroenterology of the University of Hong Kong-Shenzhen Hospital, Shenzhen, China; and Assistant Dean (Interdisciplinary Collaboration, Research Sub-Deanery), LKS Faculty of Medicine, The University of Hong Kong.

Since 2020 Prof. Seto is ranked annually by Clarivate Analytics in the top 1% worldwide by research. He has published more than 350 international journal articles and book chapters, including leading-authored articles in the Lancet, Nature Reviews Gastroenterology & Hepatology, Journal of Clinical Oncology, Lancet Global Health, Journal of Hepatology, Gut, Hepatology, Cancer Communications and npj Digital Medicine, majority related to research on chronic liver diseases. He has secured a total of over 35 million HKD in external competitive grant funding, has over 140 local, regional and international invited lectureships. He has filed 8 patents and is a principal investigator of over 20 phase I-III international industry-sponsored clinical trials.

Prof. Seto has been awarded the HKU Outstanding Researcher Award; the American Gastroenterological Association Fellowship; Sir David Todd Lectureship, Hong Kong College of Physicians; the Asia-Pacific Digestive Week Emerging Leader from the APDW Federation and the Guangdong Province Outstanding Young Medical Talent Award. He serves on multiple advisory panels in the HKSAR Government and in the Hong Kong Science and Technology Parks Corporation. He has been appointed as the Congress President of the Asia Pacific Disease Week 2027 in Hong Kong.

司徒偉基教授 2003年學校香港大學李嘉誠醫學院，並於2010年完成香港醫學專科學院内科（腸胃肝臟科）的臨床專科培訓。他隨後於2012年獲授予香港大學醫學博士。他現在為香港大學李國賢基金(腸胃學)教授，肝病研究國家重點實驗室（香港大學）主要研究員; 香港大學深圳醫院消化内科教研主管及主任醫師; 及香港大學李嘉誠醫學院助理院長（跨學科協作）。

根據《科睿唯安》(Clarivate Analytics)，司徒教授的研究自2020年起每年名列全球前 1%，他發表了 300 多篇國際期刊論文及書章，包括在《Lancet》, 《Journal of Clinical Oncology》, 《Nature Reviews Gastroenterology & Hepatology》, 《Lancet Global Health》,《Journal of Hepatology》, 《Gut》, 《Hepatology》, 《Cancer Communications》 and 《npj Digital Medicine》, 其中大部分研究與慢性肝病相關。他也主持多項研究基金項目，總金額超過3500萬港元，有140多次在本地、區域或國際的特邀講課，8項專利申報，也是20多項I-III期國際臨床試驗的主要研究員。

司徒教授被授予香港大學傑出研究院獎，美國胃腸病協會院士，廣東省衛計委傑出青年醫學人才, 亞太消化病週協會頒發Asia-Pacific Disease Week Emerging Leader，香港內科專科學院達安輝教授命名講座等獎項。他現在擔任香港特別行政區政府和香港科技園的多個諮詢委員會成員, 亦將會擔任2027亞太消化病週（香港）會議主席。

• Chronic hepatitis B （慢性乙型肝炎）: Translational and clinical studies on treatment outcomes and functional cure
• Metabolic associated fatty liver disease （代謝性脂肪肝）: Animal models, molecular mechanisms and novel medical devices
• Liver fibrosis （肝纖維化）: Novel non-invasive diagnostic techniques and clinical outcomes
• Biotechnology (生物技術): The development of novel medical devices for liver diseases
• Gut microbiota（腸道微生態）: Animal models and associations with liver disease outcomes
• Artificial intelligence （人工智能）: Deep learning and its application in liver diseases

1. Tan JT, Mao X, Lui DT, Zhang L, Cheng HM, Leung WK, Seto WK§, Cheung KS. Glycemic control is a modifiable risk factor for pancreatic cancer development in patients with diabetes: a population-based cohort study. Gut 2025 in press (§Co-corresponding). (2024 impact factor 25.8)
2. Hui RW, Chiu KW, Lee IC, Wang C, Cheng HM, Lu J, Mao X, Yu S, Lam LK, Mak LY, Cheung TT, Chia NH, Cheung CC, Kan WK, Wong TC, Chan AC, Huang YH, Yuen MF, Yu P, Seto WK. Multimodal multiphasic pre-operative image-based deep-learning predicts hepatocellular carcinoma outcomes after curative surgery. Hepatology 2025 82(2):344-356. (2024 impact factor: 16.8).
3. Mao X, Cheung KS, Tan JT, Mak LY, Lee CH, Cheng HM, Hui RW, Chan EW, Yu PL, Yuen MF, Leung WK, Seto WK. Risk of colorectal cancer and cancer-related mortality in type 2 diabetes patients treated with metformin, SGLT-2 inhibitors or their combination. Cancer Comms 2025 45(7):880-883. (2024 impact factor: 24.9).
4. Mao X, Cheung KS, Tan JT, Mak LY, Lee CH, Chiang CL, Cheng HM, Hui RW, Yuen MF, Leung WK, Seto WK. Optimal glycemic control and the reduced risk of colorectal adenoma and cancer in patients with diabetes: a population-based cohort study Gut 2024 73(8):1313-1320 (2024 impact factor 25.8).
5. Leung RH, Hui RW, Mak LY, Mao X, Liu KS, Wong DK, Fung J, Seto WK§, Yuen MF. ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis B. J Hepatol 2024 81(2):218-226. (§Co-corresponding). (2024 impact factor 33.0)
6. Mak LY, Hui RW, Lee CH, Mao X, Cheung KS, Wong DK, Lui DT, Fung J, Yuen MF, Seto WK. Glycemic burden and the risk of adverse hepatic outcomes in chronic hepatitis B patients with type 2 diabetes. Hepatology 2023 77(2):606-618 (2024 impact factor: 16.8).
7. Mao X, Peng C, Mak LY, Cheng HM, Fung J, Peleg N, Leung H, Kumar R, Lee JH, Shlomai A, Yuen MF, Seto WK. Steatosis, HBV-related hepatocellular carcinoma, cirrhosis and HBsAg seroclearance: a systematic review and meta-analysis. Hepatology 2023 77(5):1735-1745 (2024 impact factor: 16.8).
8. Su S, Wong WC, Zou Z, Cheng DD, Ong JJ, Chan P, Ji F, Yuen MF, Zhaung G, Seto WK§, Zhang L. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation. Lancet Glob Health 2022 10(2):e278-287 (§Co-corresponding) (2024 impact factor: 18.0)
9. Wong WC, Marley G, Li J, Yan W, Chan PL, Tucker JH, Tang W, Ni Y, Cheng DD, Cong L, Seto WK. Digital crowdsourced intervention to enhance viral hepatitis testing in primary care: a randomized controlled trial in China. npj Digital Medicine 2022 19;59(1):95 (2024 impact factor 15.1).
10. Seto WK, Liu KS, Mak LY, Cloherty G, Wong DK, Gersch J, Lam YF, Cheung KS, Chow N, Ko KL, To WP, Fung J, Yuen MF. Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian chronic hepatitis B patients suitable for entecavir cessation. Gut 2021 70:775-783 (2024 impact factor 25.8).
11. Mak LY, Hui RW, Fung J, Liu F, Wong DK, Cheung KS, Yuen MF, Seto WK. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol 2020;73:800-806 (2024 impact factor 33.0).
12. Seto WK, Mak SK, Chiu K, Vardhanabhuti V, Wong HF, Leong HT, Lee PS, Ho YC, Lee CK, Cheung KS, Yuen MF, Leung WK. Magnetic resonance cholangiogram patterns and clinical profiles of ketamine-related cholangiopathy in drug users. J Hepatol 2018; 69:121-8 (2024 impact factor 33.0).
13. Seto WK, Lo YR, Pawlotsky JP, Yuen MF. Chronic hepatitis B virus infection. Lancet 2018; 392:2313-2324 (2024 impact factor 88.5).
14. Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu K, Gill H, Lam YF, Lau HY, Cheung KS, Lie AK, Lai CL, Kwong YL, Yuen MF. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: a prospective study. Hepatology 2017 65:1451-61 (2024 impact factor: 16.8)
15. Seto WK, Hui AJ, Wong VW, Wong GL, Liu K, Lai CL, Yuen MF, Chan HL. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicenter prospective study. Gut 2015; 64: 667-72. (2024 impact factor 25.8).
16. Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu K, Gill H, Lam YF, Lie AK, Lai CL, Kwong YL, Yuen MF. Hepatitis B reactivation in patients with prior HBV exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol 2014; 32: 3736-43. (2024 impact factor 41.9)

1. Assistant Dean (Interdisciplinary Collaboration), LKS Faculty of Medicine, The University of Hong Kong
2. Congress President, Asia Pacific Disease Week 2027, Hong Kong
3. Committee Member, World Gastroenterology Organization
4. Advisory Committee on Health and Medical Innovation, Health Bureau, HKSAR Government
5. Advisory Panel Member, Hong Kong Science and Technology Parks Corporation Institute for Translational Research Incu-Bio Assessment Panel
6. Advisory Panel Member, Hong Kong Science and Technology Parks Corporation Clinical Translational Catalyst Assessment Panel
7. Principal Investigator, State Key Laboratory of Liver Disease, The University of Hong Kong
8. Vice-President, Hong Kong Society of Gastroenterology, Hong Kong
9. Council Member, Hong Kong Association for the Study of Liver Disease, Hong Kong
10. Council Member, Hong Kong Liver Foundation, Hong Kong
11. Consultant and Chief of Division in Gastroenterology, Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen
12. Honorary Consultant, Medicine, Queen Mary Hospital, Hong Kong

Previous offices

• Assistant Hospital Chief Executive (Research), The University of Hong Kong-Shenzhen Hospital, Shenzhen (Jan 2017 – Nov 2021)
• Director, Clinical Trials Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen (Jan 2017 – Feb 2022)

1. Outstanding Researcher Award, The University of Hong Kong (2025)
2. American Gastroenterological Association Fellow (2021), American Gastroenterological Association
3. Chief Physician (主任醫師), Guangdong Province (2021)
4. Sir David Todd Lectureship (2019), Hong Kong College of Physicians
5. Asia Pacific Digestive Week Emerging Leader (2018), APDW Federation
6. Faculty Knowledge Exchange Award (2018), The University of Hong Kong
7. Outstanding Young Researcher Award (2016-2017), The University of Hong Kong
8. Guangdong Province Outstanding Young Medical Talent Award (2017), Guangdong Health Commission, Guangdong Province, China
9. Esteemed Staff Award (2017), Shenzhen Health Commission, Shenzhen, China
10. Distinguished Research Paper Award for Young Investigator (2015), Hong Kong College of Physicians
11. Distinguished Research Paper Award for Young Investigator (2014), Hong Kong College of Physicians
12. Distinguished Research Paper Award for Young Investigator (2013), Hong Kong College of Physicians
13. Distinguished Young Fellow (2013), Hong Kong Academy of Medicine

• National Key R&D Program: Prevention & Control of Emerging & Major Infectious Diseases, Ministry of Science and Technology, 2025 (co-PI: 2025ZD01906702)
• Health and Medical Research Fund, Health Bureau, 2024 (ref no: 12232096)
• Midstream Programme for Universities 2023, Innovation and Technology Commission (ref no: ITS/046/22MS)
• General Research Fund, Research Grant Council, 2022 (ref no: 17100522)
• Innovation and Technology Fund, Innovation and Technology Commission, 2021 (ref no: ITS/222/20)
• Health and Medical Research Fund, Food and Health Bureau, 2021 (ref no: 08192936)
• Gilead HBV-Treat Program, 2021 (ref no: ISR-HK-320-6099)
• Health and Medical Research Fund (Commissioned Research Program), Food and Health Bureau, 2020 (ref no: COVID190220)
• Innovation and Technology Fund, Innovation and Technology Commission, 2019 (ref no: ITS/122/18FP)
• Guangdong Natural Science Fund (General Program), 2019 (ref no: 2019A1515012003)
• Gilead Sciences CHIME Grant, 2018 (ref no: ISR-CN-18-10455)
• S. K. Yee Medical Foundation Grant, 2018 (ref no: 2171213)
• Li Shu Pui Medical Foundation Research Grant, 2018
• Health and Medical Research Fund, Food and Health Bureau, 2017 (ref no: 14150791)
• General Research Fund, Research Grant Council, 2016 (ref no: 17125916)
• Beat Drug Fund, Security Bureau, 2015 (ref no: 140031)
• S. K. Yee Medical Foundation Grant, 2015 (ref no: 2151210)
• S. K. Yee Medical Foundation Grant, 2014 (ref no: 2141213)
• Health and Medical Research Fund, Food and Health Bureau, 2013 (ref no: 12111842)
• Young Investigator Research Grant 2012, Hong Kong College of Physicians